drugset / Trial / NCT07325136
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Timeline
- Start
- 2026-02-03
- Primary completion
- 2029-04-23
- Completion
- 2029-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986525 | Unknown | — | — |
| Subject | Pumitamig | Protein / enzyme biologic | — | — |